Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz)

Bio-Manguinhos is the Immunobiological Technology Institute of the Oswaldo Cruz Foundation (Fiocruz), serving as the primary provider of vaccines, diagnostics, and biopharmaceuticals for the Brazilian Ministry of Health. Founded in 1976, it plays a strategic role in Brazil's public health by ensuring self-sufficiency in essential biological products. The institute is one of the largest vaccine producers in Latin America, notably manufacturing the Yellow Fever vaccine and the Oxford-AstraZeneca COVID-19 vaccine. Its portfolio includes a wide range of monoclonal antibodies and recombinant proteins for treating chronic and rare diseases. Bio-Manguinhos also invests heavily in R&D and technology transfer partnerships with global pharmaceutical companies to modernize Brazil's industrial health complex.